Filtered By:
Condition: Heart Attack
Drug: Pradaxa
This page shows you your search results in order of relevance. This is page number 10.
Order by Relevance | Date
Total 172 results found since Jan 2013.
Practical Considerations for Using Novel Oral Anticoagulants in Patients With Atrial Fibrillation
Abstract
Novel oral anticoagulants, including dabigatran, rivaroxaban, and apixaban, represent new options for preventing stroke in patients with atrial fibrillation, as shown by the results from large, randomized phase III trials. Because of their greater specificity, rapid onset of action, and predictable pharmacokinetics, the novel oral anticoagulants (dabigatran, rivaroxaban, and apixaban) address several limitations of warfarin or other vitamin K antagonists in day‐to‐day clinical practice. However, a range of practical questions relating to the novel oral anticoagulants has emerged, including topics such as patie...
Source: Clinical Cardiology - November 19, 2013 Category: Cardiology Authors: Irene Savelieva, A. John Camm Tags: Review Source Type: research
Meta-Analysis of Randomized Controlled Trials on Risk of Myocardial Infarction from the Use of Oral Direct Thrombin Inhibitors
In conclusion, our data suggest that oral DTIs were associated with increased risk of MI. This increased risk appears to be a class effect of these agents, not a specific phenomenon unique to dabigatran or protective effect of warfarin. These findings support the need for enhanced postmarket surveillance of oral DTIs and other novel agents.
Source: The American Journal of Cardiology - September 27, 2013 Category: Cardiology Authors: Ramin Artang, Eric Rome, Jørn Dalsgaard Nielsen, Humberto J. Vidaillet Tags: Review Source Type: research
Increased risk of myocardial infarction with dabigatran: fact or fiction?
Dabigatran is a direct, competitive inhibitor of thrombin recently approved for the prophylaxis of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. In some of the clinical trials evaluating the efficacy and safety of dabigatran in different clinical settings [i.e., prevention of venous thromboembolism (VTE) after orthopedic surgery, secondary prevention of VTE, and acute coronary syndromes (ACS)], a trend toward an increase in acute coronary events among patients receiving dabigatran has been reported, thus raising concerns of a possible relationship between dabigatran and myocardial infarctio...
Source: Journal of Cardiovascular Medicine - January 1, 2014 Category: Cardiology Tags: Reviews: Antithrombotic treatment Source Type: research
Target-specific oral anticoagulants in patients undergoing cardioversion.
CONCLUSION: A limited body of published evidence suggests that dabigatran and apixaban may be effective alternatives to warfarin for anticoagulation therapy in patients with AF undergoing cardioversion. Careful consideration of the risks and benefits of TSOA versus warfarin use and patient preferences are key factors in appropriate drug selection.
PMID: 24973374 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - July 2, 2014 Category: Drugs & Pharmacology Authors: Law EH, Gordon W Tags: Am J Health Syst Pharm Source Type: research
Role of new oral antithrombin in management of thrombophilia presented with multiple infarctions (cerebral, myocardial and pulmonary embolism)
Publication date: Available online 5 January 2015 Source:Egyptian Journal of Chest Diseases and Tuberculosis Author(s): Mohamed Abdelwahab , Ayman El-Dib , Mohamed Hantera , Ayman A. Al-azzouny Background Thromboembolic disease is a major cause of mortality and morbidity Current anticoagulant therapies have several caveats in the clinical use. New oral antithrombin (Dabigatran) provides comparable or superior thromboprophylaxis in multiple thromboembolic disease indications compared to standard of care. Aim of this work To evaluate the role of a new oral antithrombin, in management of thrombophilia presented with multip...
Source: Egyptian Journal of Chest Diseases and Tuberculosis - January 5, 2015 Category: Respiratory Medicine Source Type: research
Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty.
In conclusion, in RCTs of pharmacological VTE prophylaxis in patients undergoing THR or TKR, there was no difference in the incidence of post-operative AT among patients treated with NOACs, compared to those treated with enoxaparin.
PMID: 25946985 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - May 7, 2015 Category: Hematology Authors: Squizzato A, Lussana F, Cattaneo M Tags: Thromb Haemost Source Type: research
The Role of FEIBA in Reversing Novel Oral Anticoagulants in Intracerebral Hemorrhage
Conclusion
In this small case series, reversal of NOAC with FEIBA was not associated with ICH expansion or any thrombotic or hemorrhagic complications.
Source: Neurocritical Care - November 6, 2015 Category: Neurology Source Type: research
Acute myocardial infarction after switching from warfarin to dabigatran.
We present a case of an acute MI and cardiac arrest in a patient with chronic AF who had been recently switched from warfarin to dabigatran. Urgent coronary angiography, at St. Michael's hospital (Toronto, Canada), revealed evidence of thromboembolism to the distal posterior descending artery. The patient was treated medically and switched back from dabigatran to warfarin. He did well and was discharged after an uneventful stay in the coronary care unit.
PMID: 25830002 [PubMed]
Source: Oman Medical Journal - December 12, 2015 Category: Middle East Health Tags: Oman Med J Source Type: research
Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in Portugal
Conclusions Apixaban is a cost-effective alternative to warfarin and dabigatran and is dominant over rivaroxaban in AF patients from the perspective of the Portuguese national healthcare system. These conclusions are based on indirect comparisons, but despite this limitation, the information is useful for healthcare decision-makers.
Source: Revista Portuguesa de Cardiologia - January 12, 2016 Category: Cardiology Source Type: research
Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER ® , RE-COVER™ II, and RE-MEDY™
AbstractThe direct oral anticoagulants, e.g., dabigatran etexilate (DE), are effective and well tolerated treatments for venous thromboembolism (VTE). Net clinical benefit (NCB) is a useful concept in weighing potential benefits against potential harm of comparator drugs. The NCB of DE vs. warfarin in VTE treatment was compared. Post-hoc analyses were performed on pooled data from the 6-month RE-COVER ® and RE-COVER™ II trials, and data from the RE-MEDY™ trial (up to 36 months), to compare the NCB of DE (150 mg twice daily) and warfarin [target international normalized ratio (INR) 2.0–3.0]. Patients (≥18 years ol...
Source: Journal of Thrombosis and Thrombolysis - February 15, 2017 Category: Hematology Source Type: research
Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants.
ConclusionsThere is a twofold increase of the risk for AMI for DOACs, in comparison with VKAs in AF therapy. In addition results suggest that in patients with AF, during aspirin monotherapy, incidence of AMI is higher than during the use of VKAs.
Source: British Journal of Clinical Pharmacology - March 23, 2017 Category: Drugs & Pharmacology Authors: Leo M. Stolk, Frank Vries, Chiel Ebbelaar, Anthonius Boer, Tom Schalekamp, Patrick Souverein, Arina Cate ‐Hoek, Andrea M. Burden Tags: PHARMACOEPIDEMIOLOGY Source Type: research
Dabigatran Compared With Rivaroxaban vs Warfarin
To the Editor In a recent issue ofJAMA Internal Medicine, Graham et al reported that rivaroxaban use increased risks of major bleeding with nonsignificant reduction in thromboembolic stroke and increased mortality compared with dabigatran in elderly Medicare beneficiaries newly treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation (November 2011-June 2014). However, dabigatran event rates were lower than reported by Graham et al in a larger group of elderly Medicare beneficiaries newly treated with dabigatran or warfarin for nonvalvular atrial fibrillation with longer follow-up during a partially overl...
Source: JAMA Internal Medicine - May 1, 2017 Category: Internal Medicine Source Type: research
Endoscopy in Patients on Antiplatelet Agents and Anticoagulants
Opinion statementManagement of patients on anticoagulant or antiplatelet therapy undergoing endoscopy presents a balance of risks between haemorrhage due to the procedure, and thrombosis due to discontinuation of antithrombotic therapy. Haemorrhage is usually controllable endoscopically, but thrombosis could, on occasion, result in myocardial infarction or stroke, with permanent disability or death. For elective procedures, there is adequate time to plan best management of antithrombotic therapy. International guidelines have been published, but recommendations are based on limited evidence and consultation with appropriat...
Source: Current Treatment Options in Gastroenterology - May 25, 2017 Category: Gastroenterology Source Type: research
Perioperative management of new oral anticoagulants in patients undergoing elective surgery at a tertiary hospital
ConclusionConsiderable discordance exists between guideline recommendations and perioperative NOAC management. Assistive tools are required that better align decision making with current best practice.
Source: Internal Medicine Journal - June 7, 2017 Category: Internal Medicine Authors: Henry Wamala, Ian A Scott, Xenia Caney Tags: Original Article Source Type: research
Thrombocytopenia induced by dabigatran: two case reports
Vitamin K inhibitors (e.g. warfarin) and indirect thrombin inhibitors (e.g. heparin) are widely used to prevent thromboembolic disorders (e.g. myocardial infarction, venous thromboembolism, and stroke). These ...
Source: BMC Neurology - June 29, 2017 Category: Neurology Authors: Hyun Goo Kang, Seung Jae Lee, Ji Yeon Chung and Jin Sung Cheong Source Type: research
